Simultaneous measurement of 92 serum protein biomarkers for the development of a multiprotein classifier for ovarian cancer detection

Amy P Skubitz, Kristin L Boylan, Kate Geschwind, Qing Cao, Tim Starr, Melissa A Geller, Joseph Celestino, Robert C. Bast, Karen H. Lu, Joe Koopmeiners

Research output: Contribution to journalArticle

Abstract

The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibodybased detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera fromeach of 61 womenwith ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly (P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4% at a specificity of 98%. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4% at a specificity of 98%, thereby improving the sensitivity and specificity of CA125 alone.

Original languageEnglish (US)
Pages (from-to)171-183
Number of pages13
JournalCancer Prevention Research
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Ovarian Neoplasms
Blood Proteins
Biomarkers
Proteins
Sensitivity and Specificity
Tumor Biomarkers
Serum
ROC Curve
Area Under Curve
Cluster Analysis
Technology
Polymerase Chain Reaction
Population
Neoplasms

Cite this

Simultaneous measurement of 92 serum protein biomarkers for the development of a multiprotein classifier for ovarian cancer detection. / Skubitz, Amy P; Boylan, Kristin L; Geschwind, Kate; Cao, Qing; Starr, Tim; Geller, Melissa A; Celestino, Joseph; Bast, Robert C.; Lu, Karen H.; Koopmeiners, Joe.

In: Cancer Prevention Research, Vol. 12, No. 3, 01.03.2019, p. 171-183.

Research output: Contribution to journalArticle

@article{5221b0e4af724c70b46df92d6354414a,
title = "Simultaneous measurement of 92 serum protein biomarkers for the development of a multiprotein classifier for ovarian cancer detection",
abstract = "The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibodybased detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera fromeach of 61 womenwith ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly (P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4{\%} at a specificity of 98{\%}. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4{\%} at a specificity of 98{\%}, thereby improving the sensitivity and specificity of CA125 alone.",
author = "Skubitz, {Amy P} and Boylan, {Kristin L} and Kate Geschwind and Qing Cao and Tim Starr and Geller, {Melissa A} and Joseph Celestino and Bast, {Robert C.} and Lu, {Karen H.} and Joe Koopmeiners",
year = "2019",
month = "3",
day = "1",
doi = "10.1158/1940-6207.CAPR-18-0221",
language = "English (US)",
volume = "12",
pages = "171--183",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Simultaneous measurement of 92 serum protein biomarkers for the development of a multiprotein classifier for ovarian cancer detection

AU - Skubitz, Amy P

AU - Boylan, Kristin L

AU - Geschwind, Kate

AU - Cao, Qing

AU - Starr, Tim

AU - Geller, Melissa A

AU - Celestino, Joseph

AU - Bast, Robert C.

AU - Lu, Karen H.

AU - Koopmeiners, Joe

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibodybased detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera fromeach of 61 womenwith ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly (P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4% at a specificity of 98%. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4% at a specificity of 98%, thereby improving the sensitivity and specificity of CA125 alone.

AB - The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibodybased detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera fromeach of 61 womenwith ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly (P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4% at a specificity of 98%. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4% at a specificity of 98%, thereby improving the sensitivity and specificity of CA125 alone.

UR - http://www.scopus.com/inward/record.url?scp=85062419570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062419570&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-18-0221

DO - 10.1158/1940-6207.CAPR-18-0221

M3 - Article

VL - 12

SP - 171

EP - 183

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 3

ER -